C4 Therapeutics, Inc.

CCCC Healthcare Biotechnology

C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024. In the quarter to June 2026, revenue grew 2.75%, EPS grew 51.4% and free cash flow grew 86.8%, each against the same quarter a year earlier.

2.77 0.01 −0.36%
Market cap
$342.0M
P/E
0.0×
Fwd P/E
−4.1×
Dividend yield
—
F-score
4/9
Altman Z
−2.16
Beneish M
−2.61
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
5.35 4.40 9.51 17.42
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(5.16) (7.15) (11.07) (387.77)
P/B ratio
1.04 0.62 1.42 2.47
Price to Tangible BV
1.04 0.62 1.42 2.47
EV/Sales
(0.39) (1.98) 3.29 10.72
EV/EBITDA
0.09 0.61 0.00 0.00
EV/Operating CF
0.13 0.72 (1.20) (4.43)
EV/FCF
0.12 0.72 (1.20) (4.40)
Quick Ratio
5.52 7.60 8.75 5.29
Current Ratio
5.76 7.81 9.00 5.45
Net Debt/EBITDA
5.57 10.54 8.28 9.64
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.09 0.10 0.11 0.11
Operating CF/Net income
0.97 1.08 1.19 0.07
Capex/Depreciation
7.47 0.03 0.09 (0.35)
Interest Coverage
— 4.61 10.46 9.48
Research and Development Expense of Revenue
231.42% 226.78% 399.97% 368.48%
Selling, General and Administrative Expense of Revenue
79.43% 83.32% 151.67% 129.39%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
40.90% 36.37% 43.42% 45.72%
Graham Net Nets
0.59 0.98 0.45 0.25
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(75.23%) (71.20%) (45.25%) (21.41%)
Free Cash Flow Yield
(59.01%) (62.72%) (28.96%) (13.99%)
Revenue per Share
0.15 0.13 0.05 0.05
Operating CF per Share
(0.43) (0.27) (0.24) (0.01)
Capex per Share
(0.01) 0.00 0.00 0.00
Free Cash Flow per Share
(0.44) (0.27) (0.24) (0.01)
Cash per Share
2.64 3.00 1.87 1.94
Shareholders Equity per Share
2.13 3.10 1.86 1.89
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.13 3.10 1.86 1.89
Free Cash Flow
(31.62) (22.16) (30.01) (1.61)
Working Capital
170.92 225.08 218.12 214.66
Capital Expenditures
(0.41) (0.01) (0.06) (0.04)
Net Current Asset Value
95.78 155.62 150.76 150.76
EV/EBIT
0.09 0.62 0.00 0.00
Capex to Sales
0.04 0.00 0.01 0.01
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
8.44 2.75 5.46 1.75
Average Payables
1.42 1.09 0.73 1.67
Average Assets
320.77 354.34 324.19 327.97
Average Common Equity
198.53 236.29 214.69 210.66

Fold the line items

Columns are period end dates